Anadys hepatitis C drug shows promise, shares jump Print E-mail
By Wire Reports   
Tuesday, 11 August 2009 13:39
Anadys Pharmaceuticals Inc (Nasdaq:ANDS) said its experimental oral hepatitis C drug showed promise in an early-stage trial, sending its shares up as much as 28 percent.

The drug ANA773 was tested in a trial that evaluated safety and tolerability and viral load decline, a measure of the severity of a viral infection, and other measures of immune response, Anadys said.

Anadys, which suspended development of ANA773 in June to focus on its lead hepatitis C drug, ANA598, plans to seek partnership opportunities to continue development of ANA773.

"With this data in hand, Anadys is positioned to find a partner who has the capital and the resources to continue the clinical development of ANA773," ThinkEquity LLC analyst Jason Kolbert said by phone.

Kolbert said major hepatitis C drugmakers, including Roche Holding AG and Schering-Plough, make the most attractive companies to partner ANA773 because the development of the program will take a long time.

Kolbert, who upgraded Anadys shares to "buy" from "accumulate," said this program adds $1 of incremental value to Anadys story, and raised his price target to $4 from $3.

"This is the only immunomodulator in development and so when we look at the hepatitis C paradigm, we believe that a drug like ANA773 when combined with specifically targeted antiviral therapy for hepatitis C (STAT-C) can help achieve the elimination of interferon," he said.

STAT-C uses a more direct approach than interferon-based therapies by targeting the hepatitis C virus, while interferon, which is the current standard of care treatment for hepatitis C, works by modifying the immune system.

"ANA773 has demonstrated a significant short-term antiviral response in HCV patients, comparable to many historical reports of interferon as a single agent," Anadys Chief Executive Steve Worland said in a statement.

Last month, U.S. health regulators cleared the parameters for a mid-stage study of Anadys' lead hepatitis C drug, ANA598. [ID:nBNG445649]

Shares of the company touched a high of $3.06 before paring some gains and were up 10 percent at $2.61 in late morning trade on Nasdaq.

(Editing by Gopakumar Warrier)




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter